NEW YORK—Covington advised the underwriters of the $122.7 million initial public offering of common stock of Codex DNA, Inc. Codex DNA is now listed on the Nasdaq Global Select Market under the ticker symbol “DNAY.”
Codex DNA is a synthetic biology company focused on enabling researchers rapidly, accurately, and reproducibly to build or “write” high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology enabled markets.
The Covington capital markets team included Donald Murray, Lilit Kazangyan, Erica Wu, and Tyler Cochrane.